checkAd

    Carl Zeiss Meditec AG  1180  0 Kommentare Carl Zeiss Meditec improves its results in first six months of financial year 2012/2013

    Carl Zeiss Meditec AG / Carl Zeiss Meditec AG : Carl Zeiss Meditec improves its results in first six months of financial year 2012/2013 . Processed and transmitted by Thomson Reuters ONE. The issuer is solely responsible for the content of this announcement.

    Revenue grows to € 443 million; positive trend for intraocular lenses and in microsurgery

    Anzeige 
    Handeln Sie Ihre Einschätzung zu Carl Zeiss Meditec AG!
    Long
    108,03€
    Basispreis
    0,91
    Ask
    × 12,63
    Hebel
    Short
    125,69€
    Basispreis
    1,02
    Ask
    × 11,50
    Hebel
    Präsentiert von

    Den Basisprospekt sowie die Endgültigen Bedingungen und die Basisinformationsblätter erhalten Sie bei Klick auf das Disclaimer Dokument. Beachten Sie auch die weiteren Hinweise zu dieser Werbung.

    In the first six months of financial year 2012/2013 medical technology company Carl Zeiss Meditec increased its revenue by 2.6% compared with the same period of the previous year, to € 443 million. Earnings before interest and tax improved to € 64.1 million (previous year: € 61.1 million); the EBIT margin rose to 14.5% (previous year: 14.1 percent).

    JENA, 14 May 2013
    Fuelled by persistently dynamic growth in the intraocular lens business and a continued positive trend in Microsurgery, the Company further increased its revenue and earnings. As reported in the ad hoc disclosure in April, the first-quarter revenue deficit in the Ophthalmic Systems business was reduced, although this took longer than was anticipated at the end of the first quarter.
    "Our widespread presence in various business fields and regions enables us to even out any fluctuations in business and to continue our long-term growth trend," says Dr. Ludwin Monz, President and CEO of Carl Zeiss Meditec AG. "We are therefore sticking firmly to our innovation strategy, the expansion of our business in the growth markets and to our overriding objectives." 

    Revenue by business unit 

    Once again, the largest revenue contribution in the first half of the year came from the Microsurgery strategic business unit (SBU). Bolstered by a continued rise in demand for visualization systems for microsurgery, this SBU achieved revenue growth of 6% to € 206.7 million (previous year: € 195.1 million).
    The Ophthalmic Systems SBU was affected by a high level of competition. The effects of the model change in the area of optical coherence tomography (OCT) also impacted this SBU. A 4.9% decline in revenue to € 175.8 million was countered in the first six months of the year by a positive trend in incoming orders, which slightly surpasses the previous year's level.
    The development of business in the Surgical Ophthalmology SBU was very positive in the first six months of the year. The double-digit revenue growth (+16.4%) to € 60.5 million, compared with € 51.9 million in the same period of the previous year, is mainly due to very good sales figures in the premium segment for intraocular lenses for minimally invasive cataract surgery. The picture in terms of reporting regions was once again quite mixed in the first six months of the year. Although there were positive impulses from both China and Japan and Latin America, as well as very good contributions to growth from Germany and Russia, business was characterized by consumer reticence in the USA and a decline in Southern Europe.  Overall, this resulted in growth of 2.1% in the EMEA region, a largely stagnating development in the Americas (-0.1%) and a continuation of robust growth, even after the inclusion of significant currency effects, of 5.9% in the Asia/Pacific region.

    Seite 1 von 3


    GlobeNewswire
    0 Follower
    Autor folgen

    Verfasst von GlobeNewswire
    Carl Zeiss Meditec AG Carl Zeiss Meditec improves its results in first six months of financial year 2012/2013 Carl Zeiss Meditec AG / Carl Zeiss Meditec AG : Carl Zeiss Meditec improves its results in first six months of financial year 2012/2013 . Processed and transmitted by Thomson Reuters ONE. The issuer is solely responsible for the content of this …

    Schreibe Deinen Kommentar

    Disclaimer